Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-004566-14 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canisius-Wilhelmina Hospital | OTHER |
| Onze Lieve Vrouw Hospital | OTHER |
| Catharina Ziekenhuis Eindhoven | OTHER |
| Maasstad Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The present study is designed to investigate the beneficial effects of adjunctive dexamethasone therapy in patients admitted with community-acquired pneumonia, additionally aiming at assessing what patients benefit from dexamethasone treatment mostly. A large multicenter study will be conducted comparing a 4 days dexamethasone 6 mg per os course with placebo in 600 patients and with predefined subgroup analyses planned.
Community-acquired pneumonia (CAP) is a common infection. Approximately 20 percent of all episodes of pneumonia result in hospitalization. It is the leading cause of community-acquired infection requiring intensive care unit (ICU) admission. In pulmonary infections, the release of cytokines and other inflammatory mediators from alveolar macrophages serves as a mechanism by which invading pathogens are eliminated. However, this reaction of the innate immune system can be potentially harmful when excessive release of circulating inflammatory cytokines causes damage to the patient, particularly the lung. Interest in the role of corticosteroids in the pathophysiology of critical illness has existed since the early part of the 20th century. On ICU, early treatment with corticosteroids to attenuate systemic inflammation is widespread. At the same time, outside the ICU little evidence is available on the effect of treatment with corticosteroids in patients diagnosed with CAP. Theoretically, early initiated administration of corticosteroids in the course of a CAP can lower systemic and pulmonary inflammation. This may lead to earlier resolution of pneumonia and a reduction of complications (sepsis, mortality).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dexamethasone | Active Comparator |
| |
| Placebo | Placebo Comparator | Placebo tablet, once daily for four consecutive days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexamethasone | Drug | Dexamethasone tablet 6 mg, once daily for four consecutive days |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Length of hospital stay | Discharge date will be the date on which the patient is clinically ready to be discharged (which means days of hospital stay on basis of social indication will be excluded from analyses). Median length of stay in an earlier CAP study performed in the St. Antonius Hospital in Nieuwegein was 6.5 days, thus patients will be followed during an expected average of 1 week. | Hospital admission (= day 1 = timepoint at which patient presents in hospital) until hospital discharge; participants will be followed for the duration of hospital stay, an expected average of 1 week. |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | 30 days after hospital admission (=day 1) the patient will visit the hospital for a out-patient visit. At that time, patient's status will be recorded. | day 30 |
| ICU admission | In the period the patient is admitted to the hospital, admission to the intensive care unit will be recorded (yes/no and specific date). |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | One year after admission patient's status will be recorded. | Day 365 |
| S. pneumoniae prevalence | To study the prevalence of different S. pneumoniae serotypes in The Netherlands (based on the serotype distribution of isolated strains as well as the increase of serotype specific antibodies). Serotyping will be performed in a bloodsample taken on the day of admission. |
Inclusion Criteria:
In combination with two of the following findings:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Willem Jan Bos, MD, PhD | St. Antonius Hospital | Principal Investigator |
| Jan Grutters, Prof, MD | St. Antonius Hospital | Principal Investigator |
| Rob Janssen, MD, PhD | Canisius-Wilhelmina Hospital | Principal Investigator |
| Frank Smeenk, MD, PhD | Catharina Ziekenhuis Eindhoven | Principal Investigator |
| Paul Bresser, MD, PhD | Onze Lieve Vrouwen Gasthuis | Principal Investigator |
| Stijn Konings, MD, PhD | Catharina Ziekenhuis Eindhoven | Principal Investigator |
| Willem Blok, MD, PhD | Onze Lieve Vrouwen Gasthuis | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Canisius Wilhelmina Hospital | Nijmegen | Gelderland | 6532 SZ | Netherlands | ||
| Catharina hospital Eindhoven |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21636122 | Background | Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, Voorn GP, van de Garde EM, Endeman H, Grutters JC, Bos WJ, Biesma DH. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Jun 11;377(9782):2023-30. doi: 10.1016/S0140-6736(11)60607-7. Epub 2011 Jun 1. | |
| 33446608 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000098968 | Community-Acquired Pneumonia |
| ID | Term |
|---|---|
| D017714 | Community-Acquired Infections |
| D007239 | Infections |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D003907 | Dexamethasone |
| ID | Term |
|---|---|
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Placebo tablet, once daily for four consecutive days |
|
| hospital admission (=day 1) until hospital discharge; participants will be followed for the duration of hospital stay, an expected average of 1 week. |
| Hospital admission (= day 1) |
| Renal damage | To study acute renal damage, and its effect on outcome, in patients with CAP. A urine sample will be taken on the day of admission, on day 4 and on the outpatient visit at day 30. | Admission (=day 1) and day 30 (outpatient visist) |
| Cost-effectiveness | To study the cost-effectiveness of dexamethasone and outcome of CAP. Resource utilization will be acquired for the entire period of hospital stay for each individual patient. | Hospital discharge; participants will be followed for the duration of hospital stay, an expected average of 1 week. |
| Post-infectious fatigue | To study post-infectious fatigue that occurs in certain patients after a CAP episode. On day 1, day 4, day of discharge, and 30 and 90 days after admission, the patient will be asked to fill in the EQ-5D questionnaire. Furthermore, on day 4, 30 and 90 days after admission, the patient will be asked to fill in the RAND-36 questionnaire. | Day 30 and day 90 |
| Pathogenesis of CAP at respiratory mucosa | To study the pathogenesis of CAP at the respiratory mucosa (this will be done in two of the four study centra). At the day of hospital admission a nasopharyngeal swab will be taken to determine aetiology of the respiratory mucose. 30 days after admission (during the outpatient visit) another nasopharyngeal swab will be taken to explore changes. | Day of admission (=day 1) and day 30 (outpatient visit) |
| Predefined subgroup analysis of length of stay | To study what patients admitted with CAP benefit most from dexamethasone therapy, based on predefined subgroup analysis with:
| Hospital discharge; participants will be followed for the duration of hospital stay, an expected average of 1 week. |
| Eindhoven |
| North Brabant |
| 5623 EJ |
| Netherlands |
| OLVG | Amsterdam | North Holland | 1091 AC | Netherlands |
| St. Antonius Hospital | Nieuwegein | Utrecht | 3430 EM | Netherlands |
| Derived |
| Wittermans E, Vestjens SMT, Spoorenberg SMC, Blok WL, Grutters JC, Janssen R, Rijkers GT, Smeenk FWJM, Voorn GP, van de Garde EMW, Bos WJW; Santeon-CAP Study Group; Members of the Santeon-CAP Study Group. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Eur Respir J. 2021 Aug 12;58(2):2002535. doi: 10.1183/13993003.02535-2020. Print 2021 Aug. |
| 30603378 | Derived | Vestjens SMT, Wittermans E, Spoorenberg SMC, Grutters JC, van Ruitenbeek CA, Voorn GP, Bos WJW, van de Garde EMW. Inter-hospital variation in the utilization of diagnostics and their proportionality in the management of adult community-acquired pneumonia. Pneumonia (Nathan). 2018 Dec 25;10:15. doi: 10.1186/s41479-018-0059-0. eCollection 2018. |
| D012140 |
| Respiratory Tract Diseases |
| D000072473 |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |